RxDoctor Payments Data

Madison Pachoe

Family · Encinitas, CANPI 1790354330

Payments from drug & device makers

$4,563in general payments, 2019–2025

Across 92 payments — averaging $49.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceutical Holding Company Ltd.$1K
  • AbbVie$440
  • AstraZeneca$315
  • Organon$298
  • Novo Nordisk$257
  • Shockwave Medical, Inc$222
  • plus $2K from 21 others

What the payments were for

  • Consulting fees$80018%
  • Travel & lodging$40%
  • Food & beverage$3,75882%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,563 in reported general payments places this provider in the 90th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$4,412
Medicare patients
30
Services billed
67

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban20$24,373
Rosuvastatin Calcium39$1,274
Levothyroxine Sodium65$964
Ezetimibe15$884
Estradiol13$676
Losartan Potassium56$622
Bupropion XlBupropion Hcl24$521
Atorvastatin Calcium46$449
Duloxetine Hcl31$380
Albuterol Sulfate HfaAlbuterol Sulfate22$349
Metoprolol Succinate21$348
Amlodipine Besylate65$329
Alendronate Sodium26$290
Omeprazole28$281
Fluticasone Propionate21$280

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$114$24,37320 claims
Almatica Pharma LLCSertraline Hcl$30$17614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,634 family providers in California.

Other family in Encinitas

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →